| Date | Title | Description |
| 05.03.2025 | Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference | LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executi... |
| 12.01.2025 | Mereo BioPharma Provides Update on Lead Clinical Programs | Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025
Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive EMA opinion on Europe... |
| 12.01.2025 | Mereo BioPharma Provides Update on Lead Clinical Programs | Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025
Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive EMA opinion on Europe... |
| 14.11.2024 | Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference | LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executiv... |
| 12.11.2024 | Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Setrusumab receives Breakthrough Therapy designation from the FDA
Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027
LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mer... |
| 12.11.2024 | Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Setrusumab receives Breakthrough Therapy designation from the FDA
Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027
LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mer... |
| 12.09.2024 | Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference | LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executi... |
| 13.08.2024 | Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled
New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates
Cash of $87.4 million as ... |
| 15.05.2024 | Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update | LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter e... |
| 05.03.2024 | Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference | - |
| 08.01.2024 | Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments | Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024, respectively; Additio... |
| 05.06.2023 | Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) | /EIN News/ -- Pediatric data show substantial induction of bone production in 1 week and a large increase in bone formation within 3 months of initiating monthly setrusumab treatment
Phase 3 sites beginning to screen patients
Conference cal... |
| 31.05.2023 | Mereo BioPharma to Present at the Jefferies Healthcare Conference | /EIN News/ -- LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, C... |
| 05.05.2023 | Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market | /EIN News/ -- LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it has received approval f... |
| 28.10.2022 | Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management | Mereo to Appoint Four New Directors to its Board of Directors
Rubric has Withdrawn its General Meeting Requisition Notice and Related Proposals; Agrees to Standstill Provision Through Mereo’s 2024 Annual General Meeting of Shareholders
LOND... |
| 28.10.2022 | Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management | /EIN News/ -- Mereo to Appoint Four New Directors to its Board of Directors
Rubric has Withdrawn its General Meeting Requisition Notice and Related Proposals; Agrees to Standstill Provision Through Mereo’s 2024 Annual General Meeting of Sha... |
| 24.10.2022 | Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022 | LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it will host a R&D up... |
| 21.10.2022 | Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting | Reiterates Quality and Composition of Mereo’s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo’s Strategy and Maximize Shareholder Value
Details Rubric’s Rejection of Reasonable Settlement Proposals an... |
| 18.10.2022 | Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value | Targets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Creating Milestones
Reiterates Commitment to Disciplined Capital Allocation and Management of Mereo’s P... |
| 17.10.2022 | Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease | Designation Validates Alvelestat’s Potential to Address a Serious Unmet Need
Company Plans R&D Update on Alvelestat in AATD-associated Lung Disease on October 31, 2022
LONDON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc ... |
| 03.10.2022 | Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders | Rubric has Rejected Mereo’s Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo’s Board
Mereo Reiterates Support for its Experienced, Highly Qualified Board and Urges Sharehol... |
| 26.09.2022 | Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board | Rubric Summarily Rejected the Proposal and Refused to Provide a Counteroffer
Rubric’s Second General Meeting Requisition Notice Again Fails to Satisfy Basic Requirements
of the Companies Act 2006 Which Apply to All U.K. Companies and Shareh... |
| 12.09.2022 | Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti... | Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
Continued clinical benefit observed with the combination of etigilimab and nivolumab, including in PD-L1 neg... |
| 09.09.2022 | Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR | NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”), a biopharmaceutical company focused on the development and commercialization of novel pro... |
| 31.08.2022 | Mereo BioPharma Sends Letter to Rubric Capital Management | Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
Announces Further Extension of Cash Runway into Q2 2025
LONDON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Grou... |
| 22.08.2022 | Mereo BioPharma Sends Letter to Rubric Capital Management | LONDON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today sent a letter to Rubric Capital Manageme... |
| 05.07.2022 | Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement | LONDON and MOUNTAIN VIEW, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that... |
| 02.06.2022 | Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization P... | --ACTIVATE includes 2 Complete Responses, 4 Partial Responses and 10 patients with Stable Disease as of April 2022 data cut off--
--Etigilimab safe and well tolerated, no new safety signals--
--Prioritization initiatives extend cash runway ... |
| 26.05.2022 | Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting | Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE)
1 Complete Response (CR), 2 Partial Responses (PR) and 9 cases of Stable Diseases (SD) as of the February 10, 2022 a... |
| 26.05.2022 | Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency | LONDON and REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that o... |
| 17.05.2022 | Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors | LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the app... |
| 09.05.2022 | Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema | Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period
Statistically significant reductions in the biomarkers Aα-v... |
| 06.05.2022 | Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat | LONDON and REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced it will ... |
| 06.04.2022 | Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference | LONDON and REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that ... |
| 31.03.2022 | Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights | LONDON and REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced finan... |
| 03.03.2022 | Mereo BioPharma to Hold Virtual R&D Day on Monday, March 14, 2022 | LONDON and REDWOOD CITY, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced it wi... |
| 01.03.2022 | Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors | LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the ap... |
| 10.02.2022 | Mereo BioPharma to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference | LONDON and REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that D... |
| 22.12.2021 | UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease | Alvelestat reported safe and well-tolerated in patients with COVID-19
Alvelestat, on top of standard of care resulted in a more rapid time to improvement in WHO Disease Severity score of >=2 in the first 5-7 days compared to placebo plus... |
| 22.12.2021 | UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease | Alvelestat reported safe and well-tolerated in patients with COVID-19
Alvelestat, on top of standard of care resulted in a more rapid time to improvement in WHO Disease Severity score of >=2 in the first 5-7 days compared to placebo plus... |
| 13.12.2021 | Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereo’s Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting | LONDON and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced the pr... |
| 30.11.2021 | Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors | One complete response, one partial response and four cases of stable disease observed among 15 patients in the efficacy analysis set
Etigilimab was well tolerated with a favorable safety profile
Conference call today at 8:30am ET
LONDON and... |
| 09.11.2021 | Mereo BioPharma to Present at Two Upcoming Investor Conferences | LONDON and REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that D... |
| 04.11.2021 | Data from Investigator-sponsored Trial of Mereo BioPharma’s alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting | LONDON and REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that d... |
| 26.10.2021 | Mereo Receives U.S. Orphan Drug Designation for alvelestat in Treatment of AATD | Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in
the Treatment of alpha-1 antitrypsin deficiency
London and Redwood City, Calif., October 26, 2021 - Mereo BioPharma Group plc (NASDAQ: MREO), "Mereo" or the &... |
| 26.10.2021 | Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency | LONDON and REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or the “Company”, a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that th... |
| 14.10.2021 | Mereo BioPharma : OIFE and OIF announce completion of the IMPACT Survey enrollment | Mereo BioPharma Group plc
Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) announces completion of the IMPACT Survey enrollment
Living With Osteogenesis IMPerfecta: Under... |
| 13.10.2021 | Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) announces completion of the IMPACT Survey enrollment | Living With Osteogenesis IMPerfecta: UnderstAnding Experiences Based On Community InsighT and Evidence Survey, the IMPACT SurveyMore than 2200 individual responses collected over a 3-month period from some 65 countries in 8 languagesSet to ... |
| 02.06.2021 | MEREO BIOPHARMA GROUP PLC
Mereo BioPharma : Announces Positive Interim Desmosine Data from alvelestat in BOS | Mereo BioPharma Group plc
Mereo BioPharma to Participate in a Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference
Londonand Redwood City, Calif., May 27, 2021 - Mereo BioPharma Group plc (NASDAQ: MREO) ('Mereo' or the 'Company... |
| 01.04.2021 | MEREO BIOPHARMA GROUP PLC
Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights | -- Ultragenyx Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta --
-- Further Strengthened Management Team --
-- OncXerna Global Licensing Agreement for Navicixizumab --
-- Strengthened Balance Sheet through Publ... |
| 18.02.2021 | Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference | LONDON and REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that D... |
| 12.02.2021 | Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares | LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the closing ... |
| 11.11.2020 | MEREO BIOPHARMA GROUP PLC
Mereo BioPharma : Announces Intention to Continue Listing Its Ads on Nasdaq but Plans Cancellation of Admission of Its Ordinary Sharesto Trading on Aim | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN
NOT FOR RELEASE, PUBLICATION OR DIST... |
| 11.11.2020 | Mereo BioPharma : Announces Intention to Continue Listing Its Ads on Nasdaq but Plans Cancellation of Admission of Its Ordinary Sharesto Trading on Aim | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN
NOT FOR RELEASE, PUBLICATION OR DIST... |
| 29.09.2020 | MEREO BIOPHARMA GROUP PLC
Mereo BioPharma : Interim Financial Results for the Six Months Ended June 30, 2020 and Corporate Update | Mereo BioPharma Group plc
Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update
On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020
Enrolmen... |
| 29.09.2020 | MEREO BIOPHARMA GROUP PLC
Mereo BioPharma : Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update | On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020
Enrolment resumed in Phase 2 study of alvelestat in Alpha-1 Antitrypsin Deficiency and initiated placebo-controlled Phase 1b/2 clinical trial in COVID-19 r... |
| 29.09.2020 | MEREO BIOPHARMA GROUP PLC
Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update | On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020
Enrolment resumed in Phase 2 study of alvelestat in Alpha-1 Antitrypsin Deficiency and initiated placebo-controlled Phase 1b/2 clinical trial in COVID-19 r... |
| 16.06.2020 | MEREO BIOPHARMA GROUP PLC
Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019 | LONDON and REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announc... |
| 10.04.2018 | Term Sheet — Tuesday, April 10 | BIKE SHARING WARS
The bike-sharing war is roaring in the United States following its explosive popularity in China and Europe.
Paid Content You can't secure what you can't see From ExtraHop
Jump became the first stationless bicycle service ... |
| 26.03.2018 | With Big Pharma castoffs in hand, Mereo files for $81M IPO; London's Verona sees stock surge on PhIIb COPD data | → Mereo BioPharma, a London biotech developing a pipeline of assets it snagged from Big Pharma shelves, is heading to the Nasdaq with hopes of raising around $81 million in an IPO. The company is already listed on the Londo... |
| 19.03.2018 | Homology, Unum set IPO terms; Knight pays Ardelyx $19M for tenapanor rights in Canada | → Two biotechs in Boston have set the terms for their IPOs: Homology Medicines plans to raise $100 million by offering 6.7 million shares between $14 and $16, and Unum Therapeutics is shooting for $75 million by offering 5.... |
| 30.10.2017 | Mereo bags rights to the latest AstraZeneca castoff, shifts focus; Neos rejects buyout offer | Denise Scots-Knight
→ London-based Mereo BioPharma has picked off an option on the rights to a Phase II drug from AstraZeneca, which has been steadily divesting itself of non-core or disappointing drugs. Mereo is paying $5 mil... |
| 29.07.2015 | Mereo BioPharma Raises $119M in Funding | Mereo BioPharma Group Ltd, a London, UK-based speciality biopharmaceutical company, raised $119m (c. £76.5m) in funding.
Backers included UK institutional investors Woodford Investment Management and Invesco Perpetual.
In conjunction with t... |
